Navigation Links
MGT Capital Investments Reports Third Quarter 2007 Financial Results and Provides Update on Recent Developments
Date:11/9/2007

perating expenses of $11.3 million for the nine month period ended September 30, 2006. The increase in operating expenses is attributable in part to costs related to Medicsight's IPO.

For the nine month period ended September 30, 2007, net loss was $9.8 million, or $0.25 per diluted share, compared to a net loss of $10.9 million, or $0.29 per diluted share, in the same period in 2006.

As of September 30, 2007, cash balances equivalents were $99.6 million, compared to $19.8 million at December 31, 2006. The increase in cash balance is attributable to the net proceeds of $61.1 million that the Company received following the listing of its subsidiary on the AIM market.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc is a holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (traded on the AIM market of the London Stock Exchange, under the Ticker symbol MDST) is a medical imaging software development company developing enterprise-wide Computer-Aided Detection (CAD) software which analyzes computer tomography (CT) scans for the early detection and measurement of colorectal polyps and lung lesions. Medicsight has focused on two of the leading causes of cancer-related death, colorectal cancer and lung cancer.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at http://www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor'
'/>"/>

SOURCE MGT Capital Investments, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... By Barbara Bronson Gray ... News) -- Although it,s extremely rare, colds, flu and ... of elevated risk for stroke in children, a new study ... have a stroke in the United States, said Dr. Heather ... neurology and pediatrics at the University of California, San Francisco ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... long been an option, but a new study shows that ... most common reasons women didn,t undergo reconstruction was that they ... or they were focused on their cancer treatment," said lead ... Sloan Kettering Cancer Center, in New York City. Also ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... treating cancer - using Botox. A study presented in ... shows that cancer growth could be suppressed by ... to cancer stem cells. The approach thus treated the ... safe and efficient. The researchers have thus far tested ... on humans. , The nervous system is crucial in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... University of Pittsburgh School of Medicine. , ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... July 10 Life is unfair, the economy is out ... true these statements might be, your ability to bounce back ... In his refreshing new self-help book, "Controlling Your Future: Six ... ), Richard Norgaard shows readers how to achieve total ...
... , , , , MARIETTA, Ga., July ... business executives that the top healthcare cost drivers for employers ... online webinar, hosted by Source Media, showed that lost workplace ... costly to employers. The purpose of the webinar was to ...
... Recently, students attended ... Anatomy 200 module of their Massage Therapy program at CNI College prepared them for a ... focus in this module. , ... Orange, CA (PRWEB) July 10, 2009 -- Recently, students attended a lab at a local ...
... ... can keep playing after shoulder joint replacement , ... Keystone, CO (Vocus) July 10, 2009 -- Replacing a joint in any ... not being able to return to a sport or activity. However, a new study presented ...
... A ... Hospital. , ... 2009 -- A Washington County woman is recovering well today after undergoing a new, robot-assisted ... is one of just a handful of bariatric patients in the region to benefit from ...
... July 9 Amgen (Nasdaq: AMGN ) announced ... Henderson, Ph.D., to the Company,s Board. Dr. Henderson, 48, ... School , having been the Eastman Kodak LFM Professor of ... MIT ) Sloan School since 1999. She specializes in technology ...
Cached Medicine News:Health News:'Controlling Your Future: Six Steps To A Better Life': New Self-Help Book Teaches the Art of Self-discipline, Self-control 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 3Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 4Health News:CNI College Massage Therapy Students Experience Plastination & Cadaver Lab 2Health News:Shoulder Surgery Doesn't Prevent Return to Sports, According to New Study presented at AOSSM Annual Meeting 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 3Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 4Health News:Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors 2
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Therapeutics,(Amex: CXM ) and its operating ... from a preclinical study, demonstrating a new ... for the potential,treatment of acute myocardial infarction ... Central (BMC) Cardiovascular Disorders (2008, 8:7, April,10, ...
... Regimen Designed to Avoid Risk of Toxicity ... Associated with Nucleoside Class of HIV Drugs, ... ) today announced that it has initiated a Phase ... in first-line therapy of adult treatment-naive HIV-infected patients,with R5-type ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 2Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 3Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 4Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 5Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 6
Black elastomer. Smooth finish. Non-Sterile....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: